Startseite>>Signaling Pathways>> Chromatin/Epigenetics>> Histone Methyltransferase>>BAY-598

BAY-598

Katalog-Nr.GC18159

BAY-598 ist ein selektiver niedermolekularer Inhibitor von SMYD2 mit einem IC50 von 27 nM.

Products are for research use only. Not for human use. We do not sell to patients.

BAY-598 Chemische Struktur

Cas No.: 1906919-67-2

Größe Preis Lagerbestand Menge
5mg
96,00 $
Auf Lager
10mg
134,00 $
Auf Lager
25mg
216,00 $
Auf Lager
500mg
2.163,00 $
Auf Lager
1g
3.811,00 $
Auf Lager

Tel:(909) 407-4943 Email: sales@glpbio.com

Kundenbewertungen

Basiert auf Kundenrezensionen.

  • GlpBio Citations

    GlpBio Citations
  • Bioactive Compounds Premium Provider

    Bioactive Compounds Premium Provider

Sample solution is provided at 25 µL, 10mM.

Product has been cited by 1 publications

Description Protocol Chemical Properties Product Documents Related Products

BAY-598 is a potent, peptide-competitive chemical probe for SET and MYND domain-containing protein 2 (SMYD2), a lysine methyl transferase inhibitor that dimethylates histone H3K36 and methylates histone H3K4. SMYD2 also methylates Lys-370 of p53, leading to decreased DNA-binding activity. SMYD2 is over-expressed in several cancers with poor prognosis. BAY-598 inhibits in vitro methylation of p53K370 with an IC50 value of 27 nM and in cells with an IC50 value < 1 μM. BAY-598 is more than 100-fold selective over other histone methyltransferases and non-epigenetic targets.

References

[1]. Reynoird N, et al. Coordination of stress signals by the lysine methyltransferase SMYD2 promotes pancreaticcancer. Genes Dev. 2016 Apr 1;30(7):772-85.

Bewertungen

Review for BAY-598

Average Rating: 5 ★★★★★ (Based on Reviews and 4 reference(s) in Google Scholar.)

5 Star
100%
4 Star
0%
3 Star
0%
2 Star
0%
1 Star
0%
Review for BAY-598

GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.

Required fields are marked with *

You may receive emails regarding this submission. Any emails will include the ability to opt-out of future communications.